Javier Cortés
Impact in
- Oncology top 0.01%
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Cancer Immunotherapy and Biomarkers
- Cancer Cells and Metastasis
- Cancer Research top 0.05%
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
Papers in
- Oncology 387
- HER2/EGFR in Cancer Research 198
- Cancer Treatment and Pharmacology 108
- Cancer Immunotherapy and Biomarkers 59
- Cancer Cells and Metastasis 25
- Cancer Research 152
- Breast Cancer Treatment Studies 107
- Cancer Genomics and Diagnostics 46
- Co-authors
- José Baselga (18 shared papers)Graham A. Ross (10 shared papers)Sandra M. Swain (14 shared papers)Nadia Harbeck (38 shared papers)Emma Clark (9 shared papers)Sung‐Bae Kim (12 shared papers)Andreas Schneeweiß (17 shared papers)Fátima Cardoso (19 shared papers)
- Journals
- Annals of Oncology (113 papers)ESMO Open (31 papers)Journal of Clinical Oncology (28 papers)European Journal of Cancer (26 papers)Clinical Cancer Research (24 papers)
- Partner nations
- SpainUnited StatesUnited Kingdom
In The Last Decade
Javier Cortés
624 papers receiving 51.4k citations
Javier Cortés's Hit Papers
Peers
Comparison fields: 5 of 175
- Oncology 29.4k
- Cancer Research 11.4k
- Pulmonary and Respiratory Medicine 13.5k
- Radiology, Nuclear Medicine and Imaging 6.1k
- Genetics 2.5k
Countries citing papers authored by Javier Cortés
This map shows the geographic impact of Javier Cortés's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Javier Cortés with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Javier Cortés more than expected).
Fields of papers citing papers by Javier Cortés
This network shows the impact of papers produced by Javier Cortés. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Javier Cortés. The network helps show where Javier Cortés may publish in the future.
Co-authors
The 25 scholars most cited alongside Javier Cortés, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 650 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Pembrolizumab for Early Triple-Negative Breast Cancer Hit paper breakdown → | 2020 | 2258 |
| 2 | Breast cancer Hit paper breakdown → | 2019 | 2256 |
| 3 | Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer Hit paper breakdown → | 2011 | 2024 |
| 4 | Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer Hit paper breakdown → | 2015 | 1669 |
| 5 | Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer Hit paper breakdown → | 2019 | 1575 |
| 6 | Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial Hit paper breakdown → | 2020 | 1374 |
| 7 | Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer Hit paper breakdown → | 2021 | 1197 |
| 8 | 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) Hit paper breakdown → | 2020 | 1014 |
| 9 | ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer Hit paper breakdown → | 2021 | 993 |
| 10 | Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA) Hit paper breakdown → | 2013 | 948 |
| 11 | Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study Hit paper breakdown → | 2011 | 919 |
| 12 | 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4) Hit paper breakdown → | 2018 | 870 |
| 13 | Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study Hit paper breakdown → | 2013 | 808 |
| 14 | Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer Hit paper breakdown → | 2022 | 791 |
| 15 | Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer Hit paper breakdown → | 2010 | 776 |
| 16 | Expression of p95HER2, a Truncated Form of the HER2 Receptor, and Response to Anti-HER2 Therapies in Breast Cancer Hit paper breakdown → | 2007 | 730 |
| 17 | Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE) Hit paper breakdown → | 2020 | 721 |
| 18 | Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma Hit paper breakdown → | 2015 | 690 |
| 19 | Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study Hit paper breakdown → | 2020 | 668 |
| 20 | Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study Hit paper breakdown → | 2018 | 668 |
About Javier Cortés
Javier Cortés is a scholar working on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Molecular Biology, having authored 650 papers that have together received 52.5k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (198 papers), Advanced Breast Cancer Therapies (123 papers), Cancer Treatment and Pharmacology (108 papers), Breast Cancer Treatment Studies (107 papers), Cancer Immunotherapy and Biomarkers (59 papers), Cancer Genomics and Diagnostics (46 papers), Monoclonal and Polyclonal Antibodies Research (38 papers) and Cancer Cells and Metastasis (25 papers). The work is most often cited by research in Oncology (29.4k citations), Cancer Research (11.4k citations), Pulmonary and Respiratory Medicine (13.5k citations), Radiology, Nuclear Medicine and Imaging (6.1k citations) and Genetics (2.5k citations). Javier Cortés has collaborated with scholars based in Spain, United States and United Kingdom. Frequent co-authors include José Baselga, Graham A. Ross, Sandra M. Swain, Nadia Harbeck, Emma Clark, Sung‐Bae Kim, Andreas Schneeweiß, Fátima Cardoso, José Baselga and Mark C. Benyunes. Their work appears in journals such as Annals of Oncology, ESMO Open, Journal of Clinical Oncology, European Journal of Cancer and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.